8-K: FDA Accepts Corcept's Relacorilant NDA for Ovarian Cancer

The FDA has accepted Corcept Therapeutics' New Drug Application for relacorilant as a treatment for platinum-resistant ovarian cancer, setting a PDUFA date of July 11, 2026.

Summary

• The U.S. Food and Drug Administration (FDA) has accepted Corcept Therapeutics' New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
• The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026, for the relacorilant NDA for ovarian cancer.
• The NDA is based on positive data from the company's pivotal Phase 3 ROSELLA and Phase 2 trials.
• In these trials, patients treated with relacorilant plus nab-paclitaxel demonstrated improved progression-free and overall survival compared to those receiving nab-paclitaxel monotherapy.
• Relacorilant was well-tolerated, with the safety profile in combination arms similar to nab-paclitaxel monotherapy, and did not require biomarker selection.
• Relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist, also under development for endogenous hypercortisolism and prostate cancer.
• Platinum-resistant ovarian cancer is a severe condition with few treatment options, affecting approximately 20,000 women annually in the United States and at least an equal number in Europe.

Sentiment

Score: 8

Explanation: The FDA's acceptance of the NDA for relacorilant for a severe, unmet medical need like platinum-resistant ovarian cancer, backed by positive Phase 3 data, is a significant positive milestone. It de-risks the regulatory pathway considerably and opens up a substantial market opportunity. The long PDUFA date (July 2026) means the market impact might be spread out, but the news is fundamentally strong.

Positives

• FDA acceptance of the New Drug Application for relacorilant for platinum-resistant ovarian cancer, marking a significant regulatory milestone.
• Positive data from pivotal Phase 3 ROSELLA and Phase 2 trials demonstrating improved progression-free and overall survival for patients.
• Relacorilant exhibited a favorable safety profile, with no increase in the safety burden when combined with nab-paclitaxel.
• The treatment does not require biomarker selection, potentially allowing for broader applicability across the patient population.
• Relacorilant has been designated an orphan drug by the European Commission for the treatment of ovarian cancer, highlighting the unmet medical need.
• The drug has the potential to redefine treatment for a dire disease with limited existing options.

Future Outlook

The company anticipates potential regulatory approval for relacorilant as a treatment for patients with platinum-resistant ovarian cancer, with the FDA review process culminating in a PDUFA date of July 11, 2026. Management believes relacorilant has the potential to redefine the treatment landscape for this severe disease.

Management Comments

• "The FDA's acceptance of our NDA brings us closer to offering a much-needed treatment option to patients with this dire disease."
• "Relacorilant has the potential to redefine how platinum-resistant ovarian cancer is treated."

Industry Context

The acceptance of relacorilant's NDA addresses a significant unmet medical need in the oncology sector, specifically for platinum-resistant ovarian cancer, a condition with limited treatment options and poor prognosis. This development positions Corcept Therapeutics as a potential innovator in the targeted therapy space for cortisol-mediated diseases, expanding its presence beyond hypercortisolism into oncology. The orphan drug designation for ovarian cancer in Europe underscores the high medical need and potential market opportunity.

Comparison to Industry Standards

• Median overall survival for platinum-resistant ovarian cancer patients with single-agent chemotherapy is approximately 12 months, highlighting the dire need for more effective treatments. Relacorilant's demonstrated improvement in progression-free and overall survival in Phase 3 and Phase 2 trials, without increasing safety burden, suggests a potentially superior profile compared to current monotherapy standards.
• The absence of a requirement for biomarker selection for relacorilant contrasts with many targeted oncology therapies that necessitate specific genetic markers, potentially allowing for broader applicability across the patient population compared to more narrowly defined treatments like PARP inhibitors (e.g., Lynparza, Zejula) or bevacizumab (Avastin) which often have specific patient selection criteria or are used in earlier lines of therapy.
• The orphan drug designation by the European Commission for ovarian cancer indicates that relacorilant addresses a condition affecting a small population with high unmet need, similar to other orphan oncology drugs that receive expedited review or market exclusivity.

Stakeholder Impact

• **Shareholders**: Potential for increased shareholder value due to the advancement of a key pipeline asset towards commercialization, addressing a significant market opportunity. Regulatory acceptance de-risks the investment.
• **Patients**: Offers hope for a much-needed new treatment option for platinum-resistant ovarian cancer, a disease with limited therapeutic alternatives and poor prognosis.
• **Healthcare Providers**: Provides a potential new tool for oncologists to treat a challenging patient population, especially given the drug's favorable safety profile and lack of biomarker selection requirement.
• **Employees**: Positive news for employee morale and potential for future growth and expansion within the company.

Next Steps

• FDA review of the New Drug Application for relacorilant for platinum-resistant ovarian cancer, with a PDUFA date of July 11, 2026.
• Continued development of relacorilant for other serious disorders, including endogenous hypercortisolism (with a PDUFA date of December 30, 2025) and prostate cancer.
• Ongoing advanced clinical trials for hypercortisolism, solid tumors, ALS, and liver disease.

Key Dates

Recommendation

The FDA's acceptance of the New Drug Application for relacorilant in platinum-resistant ovarian cancer, supported by robust Phase 3 data showing improved survival and a favorable safety profile, represents a major de-risking event for Corcept Therapeutics. This drug addresses a significant unmet medical need in a large market (approximately 20,000 US patients annually). While the PDUFA date is in July 2026, this milestone significantly increases the probability of approval and future revenue generation, making CORT an attractive investment for long-term growth in the oncology space. The orphan drug designation further enhances its market potential. The company's existing commercial product (Korlym) and other pipeline assets provide a solid foundation.

Keywords

Corcept Therapeutics, CORT, Relacorilant, Ovarian Cancer, Platinum-Resistant, FDA, NDA, PDUFA, Oncology, Drug Approval, Biotechnology, Pharmaceuticals, Glucocorticoid Receptor Antagonist, Cortisol Modulation